Düsseldorf, Germany

Dirk Schmidt

This inventor holds 1 USPTO granted patent. Top assignee: Schwarz Pharma Ag. Active years: 2007.


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dirk Schmidt: Innovator in Pain Treatment

Introduction

Dirk Schmidt is a notable inventor based in Düsseldorf, Germany. He has made significant contributions to the field of pain management through his innovative research and development of new compounds. His work focuses on the creation of medications that address chronic and neuropathic pain, which affects millions of individuals worldwide.

Latest Patents

Dirk Schmidt holds a patent for "Derivatives of azaspiro compounds for the treatment of pain." This invention relates to azaspiro compounds and their use as medications, particularly for the treatment of chronic, chronic-phlogistic, and/or neuropathic pain. The compounds that lend themselves particularly well to the production of analgesics include 1,3-diazaspiro[4.5]decane-2,4-dion and 1,3-diazaspiro[4.5]decane-2,4-dithion. He has 1 patent to his name, showcasing his commitment to advancing medical science.

Career Highlights

Dirk Schmidt is associated with Schwarz Pharma AG, a company known for its focus on pharmaceutical innovations. His role at the company has allowed him to explore and develop new therapeutic solutions for pain management. His dedication to research and development has positioned him as a key player in the pharmaceutical industry.

Collaborations

Dirk has collaborated with notable colleagues, including Claus Meese and Norma Selve. These partnerships have fostered an environment of innovation and creativity, leading to advancements in the treatment of pain.

Conclusion

Dirk Schmidt's contributions to the field of pain management through his innovative patents and collaborations highlight his importance as an inventor. His work continues to impact the lives of those suffering from chronic pain, making him a significant figure in the pharmaceutical industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…